Abbott Laboratories (NYSE:ABT) Updates FY 2025 Earnings Guidance

Abbott Laboratories (NYSE:ABT) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 5.100-5.200 for the period, compared to the consensus EPS estimate of 5.161. The company issued revenue guidance of -. Abbott Laboratories also updated its Q3 2025 guidance to 1.280-1.320 EPS.

Analysts Set New Price Targets

Several research firms have recently issued reports on ABT. Barclays raised their price objective on Abbott Laboratories from $158.00 to $159.00 and gave the stock an “overweight” rating in a report on Thursday, April 17th. Stifel Nicolaus raised their price objective on Abbott Laboratories from $135.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday, April 17th. Morgan Stanley raised their price objective on Abbott Laboratories from $127.00 to $137.00 and gave the stock an “equal weight” rating in a report on Tuesday. Jefferies Financial Group lifted their target price on Abbott Laboratories from $135.00 to $137.00 and gave the company a “hold” rating in a report on Thursday, April 17th. Finally, Evercore ISI lifted their target price on Abbott Laboratories from $140.00 to $145.00 and gave the company an “outperform” rating in a report on Tuesday, July 8th. Six equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $144.33.

Abbott Laboratories Trading Up 0.2%

NYSE:ABT opened at $131.79 on Thursday. The business’s 50-day moving average is $133.43 and its two-hundred day moving average is $129.32. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.78 and a quick ratio of 1.27. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $141.23. The firm has a market capitalization of $229.30 billion, a PE ratio of 17.09, a price-to-earnings-growth ratio of 2.50 and a beta of 0.73.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.25 by $0.01. Abbott Laboratories had a return on equity of 19.01% and a net margin of 31.89%. Research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th will be given a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.79%. The ex-dividend date of this dividend is Tuesday, July 15th. Abbott Laboratories’s payout ratio is 30.61%.

Insider Activity

In other news, Director Sally E. Blount sold 2,600 shares of Abbott Laboratories stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total transaction of $337,116.00. Following the sale, the director directly owned 34,058 shares of the company’s stock, valued at approximately $4,415,960.28. The trade was a 7.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.46% of the company’s stock.

Institutional Trading of Abbott Laboratories

A hedge fund recently raised its stake in Abbott Laboratories stock. Brighton Jones LLC boosted its position in Abbott Laboratories (NYSE:ABT) by 10.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 51,719 shares of the healthcare product maker’s stock after buying an additional 4,755 shares during the quarter. Brighton Jones LLC’s holdings in Abbott Laboratories were worth $5,850,000 at the end of the most recent quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.